Description |
transforming growth factor beta 2 |
transforming growth factor beta receptor 2 |
Image |
|
|
GO Annotations |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
|
|
Diseases |
|
|
GWAS |
- Acne (severe) ( 24927181 30542056)
- Body fat distribution (leg fat ratio) ( 30664634)
- Body fat distribution (trunk fat ratio) ( 30664634)
- Bone mineral density (hip) ( 30172743)
- Central corneal thickness ( 32528159 29760442)
- Chronic obstructive pulmonary disease ( 28166215 30804561)
- Chronic obstructive pulmonary disease (severe) ( 24621683)
- Diastolic blood pressure ( 30224653)
- Diffusing capacity of carbon monoxide ( 30694715)
- Emphysema imaging phenotypes ( 26030696)
- FEV1 ( 30804560)
- Gemcitabine-induced early high-grade neutropenia in pancreatic cancer ( 30889042)
- Heel bone mineral density ( 30598549)
- Height ( 20881960 25282103 25429064 31562340)
- Hip circumference adjusted for BMI ( 34021172 25673412)
- Hip minimal joint space width ( 27701424)
- Intraocular pressure ( 29617998)
- Local histogram emphysema pattern ( 25006744)
- Lung function (FEV1/FVC) ( 30804560)
- Lung function (FVC) ( 30804560)
- Peak expiratory flow ( 30804560)
- Post bronchodilator FEV1 ( 26634245)
- Post bronchodilator FEV1/FVC ratio ( 26634245)
- Pulmonary function ( 21946350)
- Refractive error ( 32231278)
- Rosacea symptom severity ( 29771307)
- Systolic blood pressure ( 30578418)
- Vertical cup-disc ratio (adjusted for vertical disc diameter) ( 31959993)
- Vertical cup-disc ratio (multi-trait analysis) ( 31959993)
- Waist circumference adjusted for BMI (adjusted for smoking behaviour) ( 28443625)
- Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) ( 28448500)
- Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625)
- Waist circumference adjusted for BMI in active individuals ( 28448500)
- Waist circumference adjusted for BMI in non-smokers ( 28443625)
- Waist circumference adjusted for body mass index ( 34021172 25673412 28448500)
|
- Breast cancer ( 29059683 23535729)
- Cellular nuclear factor (erythroid-derived 2)-like 2 levels ( 30767168)
- Cognitive decline rate in late mild cognitive impairment ( 26252872)
- Estimated glomerular filtration rate ( 31152163)
- Heel bone mineral density ( 30598549)
- Metabolite levels ( 23823483)
- Migraine ( 22683712 27322543)
- Migraine - clinic-based ( 23793025)
- Night sleep phenotypes ( 27126917)
- Postprandial triglyceride response ( 32603185)
- Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab) ( 25117820)
- Systolic blood pressure ( 30224653)
- Tonometry ( 17903302)
|
Interacting Genes |
17 interacting genes:
APP
BMP2
CCN2
DCN
ENG
FMOD
KMT2A
LTBP3
MARK1
PZP
TGFB1
TGFB3
TGFBR1
TGFBR2
TGFBR3
VASN
VTN
|
50 interacting genes:
ACVR1
ACVRL1
AP2B1
APP
ARHGEF6
ARHGEF7
CCNB1
CCNB2
CD44
CDK1
CLU
CTNNB1
DAB2
DAXX
DYNLT4
EIF3I
ENG
FANCC
GOPC
KCNK18
MAP2K1
NRP1
OSR1
PAK1
PDGFRA
PIK3R1
PIK3R2
PML
PPP2CB
PSMD14
RCVRN
SMAD3
SMAD4
SMAD7
SNX6
STRAP
TDGF1
TERT
TGFB1
TGFB1I1
TGFB2
TGFB3
TGFBR1
TGFBR3
TGFBRAP1
TRAP1
TRMO
TSSK1B
ZFYVE9
ZNF510
|
Entrez ID |
7042 |
7048 |
HPRD ID |
01828 |
01823 |
Ensembl ID |
ENSG00000092969
|
ENSG00000163513
|
Uniprot IDs |
P61812
Q59EG9
|
A3QNQ0
D2JYI1
P37173
|
PDB IDs |
1TFG
2TGI
4KXZ
5TX4
5TY4
6I9J
|
1KTZ
1M9Z
1PLO
2PJY
3KFD
4P7U
4XJJ
5E8V
5E8Y
5E91
5E92
5QIN
5TX4
5TY4
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
|
|
Tagcloud (Difference) ? |
|
|
Tagcloud (Intersection) ? |
|